Amgen-Sanofi patent case divides makers of antibody drugs :

Amgen Inc's battle with Sanofi and Regeneron at the U.S. Supreme Court over its cholesterol drug Repatha on Monday has some drugmakers hoping a ruling will reshape U.S. patent law and competition among companies that make antibody medicines.

Related Keywords

Washington , United States , Caroline Humer , Bristol Myers Squibb , Eli Lillys , Eli Lilly , Irena Royzman , Kramer Levin , Brian Skorney , Amgen , Thomson Reuters Trust Principles , Supreme Court , Amgen Inc , Reuters , Us Supreme Court , Global Market Insights , Patrick Wingrove Editing , Thomson Reuters Trust , Nrlin Opat , Rhpi Lawsuits , Mtpix , Bact , Biodrg , Biz , Clj , Cmpny , Cprod , Gen , Hea , Heca , Tiprop , Judic , Mrch , Phag08 , Phar , Phar08 , Phar1 , Phmr , Pol , Publ , Sci , Scotus , Wash , Gb , Weu , Gamers , Us , Europ , Ezc , Namer , Fr , Legal , Reuters Legal , Nrlin Oscotus , Nrlpa Oapp , Nrlpa Oip , Nrlpa Olit , Ef Business Future Of Health ,